At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Aug 11, 2026 at 09:30 ET
Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), and provided pipeline updates for telitacicept. Phase 3 UPSTREAM MG and UPSTREAM SjD trials are enrolling with topline data expected in 1H27. As a pre-revenue clinical-stage biotech, the filing is a routine quarterly update with no material financial surprises.
- Cash, cash equivalents and marketable securities were $466.1M as of June 30, 2026, with $48.4M additional net proceeds from ATM sales in July 2026, providing runway into early 2029.
- Net loss for Q2 2026 was $62.8M, compared to $1,573.7M in Q2 2025 (decrease primarily due to change in fair value of liability-classified warrants).
- R&D expenses were $25.9M vs $261.5M in Q2 2025; G&A expenses were $21.9M vs $12.8M.
- Enrollment ongoing in global Phase 3 UPSTREAM MG trial for generalized myasthenia gravis and UPSTREAM SjD trial for primary Sjögren's disease, with topline data from UPSTREAM MG anticipated in 1H27.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access